Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT07286032

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2026-04-30

150

Participants Needed

7

Research Sites

163 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.

CONDITIONS

Official Title

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 18 years or older at screening
  • Histologically or cytologically confirmed solid tumor (e.g., non-small-cell lung carcinoma, breast, ovarian, bladder, pancreatic, gastrointestinal, or colon/colorectal cancer)
  • Receiving platinum- and/or gemcitabine-containing chemotherapy regimens on 21-day cycles
  • Eastern Cooperative Oncology Group performance status of 0 to 2
  • Life expectancy of at least 6 months
  • Signed informed consent form and good compliance
Not Eligible

You will not qualify if you...

  • Hematopoietic diseases other than chemotherapy-induced thrombocytopenia
  • Hematologic malignancies
  • Thrombocytopenia caused by reasons other than chemotherapy within 6 months prior to Study Day 1
  • Untreated brain metastases or leptomeningeal metastasis
  • Conditions requiring emergency treatment (e.g., superior vena cava syndrome, spinal cord compression)
  • Severe cardiovascular disorders or interventions within 6 months
  • Arterial or venous thrombosis within 6 months
  • Known bleeding disorders or platelet dysfunction
  • Severe hemorrhage during screening
  • Acute or uncontrolled hepatitis B or C infection
  • Human immunodeficiency virus (HIV) infection

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Cancer and Blood Specialty Clinic

Los Alamitos, California, United States, 90254

Not Yet Recruiting

2

AdventHealth Hematology and Oncology Denver Cypress Hematology and Oncology

Denver, Colorado, United States, 80210

Not Yet Recruiting

3

Oncology & Hematology Associates of West Broward

Coral Springs, Florida, United States, 33065

Not Yet Recruiting

4

Mid-Florida Hematology & Oncology Centers, P.A.

Orange City, Florida, United States, 32763

Actively Recruiting

5

Springfield Clinic

Springfield, Illinois, United States, 62702

Not Yet Recruiting

6

Morristown Medical Center

Morristown, New Jersey, United States, 07039

Not Yet Recruiting

7

New York Cancer and Blood Specialists One Oncology

Shirley, New York, United States, 11967

Not Yet Recruiting

Loading map...

Research Team

J

Junye Xiong

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here